BT-20（人乳腺癌細胞）
CBP60354
詢 價
索取STR
產品描述
產品數據庫
| I. General information | |
| Synonyms: | BT-20 |
| Background: | This breast tumor line was established by E.Y. Lasfargues and L. Ozzello in 1958 by isolation and cultivation of cells spilling out of the tumor when it was cut in thin slices. |
| Species: | Homo sapiens, human |
| Tissue: | mammary gland/breast |
| Disease: | carcinoma |
| Gender: | female, 74 years, Caucasian |
| Morphology: | epithelial |
| Growth Mode: | adherent |
| DNA Profile: | Amelogenin: X CSF1PO: 12 D13S317: 11 D16S539: 11,14 D5S818: 12 D7S820: 10 THO1: 7,9.3 TPOX: 11 vWA: 16,17 Our Cell Line Authentication Service |
| Culture Medium: |
MEM + 10% FBS+ 1% Non Essential Amino Acids (NEAA) + 1mM Sodium Pyruvate (NaP)+10ug/ml insulin or 1% ITS-G(GIBCO 41400045) BT-20完全培養基，# CBP60354M |
| Cryopreservation medium: | 90%FBS+10%DMSO |
| Antigen Expression: | Antigen expression: HLA A1, Bw16 (+/-) |
| Tumor Formation: | Yes, in nude mice (The cells form grade II adenocarcinomas.) |
| Comments: | The cells express the WNT3 and the WNT7B oncogenes [PubMed: 8168088]. A mycoplasma contaminant was discovered and eliminated early in 1972. Growth of BT-20 cells is inhibited by tumor necrosis factor alpha (TNF alpha). BT-20 cells are negative for estrogen receptor, but do express an estrogen receptor mRNA that has deletion of exon 5. For more information, please contact us (4008-750-250). |
